Brind.

Natco Pharma and Novartis are challenging patent exclusivity of the drug ribociclib in the Delhi High Court.

1 report, 1 independent Updated Aug 5

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Natco Pharma Novartis

Keep exploring

The entities involved

Natco Pharma
Indian pharmaceutical company
- India and Natco Pharma are investing in the U.S. biotech company eGenesis.Mon 14:09
Novartis
Swiss-American multinational pharmaceutical corporation
- Novartis acquired Avidity in a $12 billion purchase, while Trump simultaneously threatened Swiss businesses with tariffs.Sat 01:46
- GSK and Novartis are identified as major pharmaceutical companies.Fri 02:16

Coverage

Newest first; wire copies grouped

Aug 5livemint.com